Muvalaplin, a drug under development at Eli Lilly, lowered lipoprotein levels by 65 percent, according to results published Aug. 28 in JAMA.
The medication could be the first treatment for lipoprotein, a genetic marker of cholesterol that increases the risk of heart attack and stroke. Lipoprotein is stickier than LDL cholesterol, and drugs indicated for LDL aren’t as effective for lipoprotein, meaning muvalaplin has potential to be the first drug to tackle “sticky” cholesterol.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
